|

Development of a Pharmacogenomic Panel for Early Detection of Chemotherapy- and Immunotherapy-Induced Cardiotoxicity.

RECRUITINGSponsored by Beneficência Portuguesa de São Paulo
Actively Recruiting
SponsorBeneficência Portuguesa de São Paulo
Started2026-05-11
Est. completion2029-03-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07663357

Summary

To evaluate the use of a pharmacogenetic and pharmacoepigenetic panel for predicting chemotherapy- and immunotherapy-induced cardiotoxicity in cancer patients.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients with a confirmed diagnosis of breast cancer who are scheduled to initiate treatment with anthracyclines and/or HER2-targeted therapies (anti-HER2 therapies).

Exclusion Criteria:

* Patients with a left ventricular ejection fraction (LVEF) \< 50%;
* Patients who have undergone chemotherapy and/or radiotherapy within the previous year;
* Patients with chronic kidney disease and a glomerular filtration rate (GFR) \< 30 mL/min/1.73 m²;
* Patients with uncontrolled hypertension;
* Patients with complex congenital heart disease.

Conditions3

CancerCardiotoxicityHeart Disease

Browse More Trials

Cancer trialsHeart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.